Quarterly report pursuant to Section 13 or 15(d)

CONDENSED BALANCE SHEETS (Unaudited)

v3.23.1
CONDENSED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 1,136 $ 2,937
Restricted cash 98 196
Receivables 8 36
Inventory 106 106
Prepaid expenses and other current assets 406 314
Discontinued operations - current assets 31 14
Total current assets 1,785 3,603
Property and equipment, net 181 224
Oher assets 48 48
Operating lease right-of-use assets, net 154 183
Total assets 2,168 4,058
Current liabilities:    
Accounts payable 567 695
Accrued clinical trials expenses 30 5
Other accrued liabilities 1,440 1,483
Operating lease liability, current 125 122
Deferred grant revenue 98 196
Discontinued operations – current liabilities 187 129
Total current liabilities 2,447 2,630
Operating lease liability, noncurrent 33 65
Total liabilities 2,480 2,695
Stockholders’ equity (deficit):    
Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized, 15,016,295 shares issued and outstanding at March 31, 2023 and December 31, 2022. 15 15
Additional paid-in capital 387,609 387,609
Accumulated deficit (387,936) (386,261)
Total stockholders’ equity (deficit) (312) 1,363
Total liabilities and stockholders’ equity $ 2,168 $ 4,058